MaxCyte Announces Collaboration with ScaleReady to Participate in the G-Rex Grant Program
Initiative will equip researchers with the resources, tools and expertise they need to develop groundbreaking cell and gene therapies at warp speed
ROCKVILLE, MD, August 29, 2024 — MaxCyte, Inc., a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced it has teamed with ScaleReady, the cell therapy manufacturing solutions expert, to participate in ScaleReady’s newly launched G-Rex® Grant Program. This $20 million initiative is designed to propel the advancement of cell and gene therapies (CGT) by providing commercial, manufacturing and academic institutions with critical resources and services to expeditiously develop and implement a G-Rex centric manufacturing platform.
“The G-Rex Grant Program represents a significant step forward in reducing the barrier to entry that many CGT companies encounter in cell and gene therapy development,” said Maher Masoud, President and CEO of MaxCyte. “Our involvement formalizes a long-standing relationship between MaxCyte and ScaleReady and ensures that G-Rex Grant Recipients will benefit from our state-of-the-art electroporation technology and extensive expertise in cell therapy development. We are able to help them transfect virtually any cell type for any application at any scale.”
“Efficient use of time and money is mission critical for every entity in the CGT field,” said John Wilson, CEO of Wilson Wolf. “The challenge is that the range of knowledge needed to achieve this efficiency is overwhelming. ScaleReady’s G-Rex Grant Program is specifically structured to solve that problem.
ScaleReady’s G-Rex Grant Program delivers what we believe is the most extensive range of expertise that has ever been made available to CGT entities at no cost to grant recipients. This is made possible through a diverse consortium of like-minded collaborators who are joining our mission to empower CGT entities with the ability to save a tremendous amount of time and money. We are happy to announce that MaxCyte will be an official partner of the G-Rex Grant Program, and we welcome their expertise in non-viral genetic engineering.
G-Rex Grant recipients can access a wide range of expertise to safely and expeditiously move through R&D and process development, negotiate favorable terms with CDMOs, create and implement a highly effective and easy-to-use quality system, and easily and quickly synchronize business and technical objectives with regulatory requirements.
We believe this collective effort will be one of the catalysts that helps to de-risk the business of CGT and reinvigorates investment in the field. All are welcome.”
Through the G-Rex Grant Program, recipients are eligible to receive the full array of collective knowledge in addition to $5,000 to $300,000 in G-Rex devices, reagents, capital equipment, application support and manufacturing consultation services. MaxCyte’s electroporation expertise and equipment are available to all grant recipients through an exclusive offer, including a discounted instrument of choice for pre-clinical work, one pack of non-GMP processing assemblies of choice and one complimentary ExPERT™ Platform Starter Pack.
MaxCyte is committed to supporting researchers and accelerating their research into the clinic, enabling cell-based manufacturing as part of a complete platform quickly and at a lower cost. “Working alongside ScaleReady, our goal is to provide clients with the resources and tools they need to achieve their milestones and bring potentially lifesaving therapies to market faster, saving them time and money,” added Mr. Masoud.
Learn more and apply for the G-Rex Grant Program at G-Rex Grant for the Advancement of CGT Development and Manufacturing.
Follow the G-Rex Grant Program on social media using these hashtags:
- #GRexGrant
- #MaxCyte
- #WeAreScaleReady
- #CellTherapy
- #GeneTherapy
- #BiotechInnovation
- #LifeSciences
MaxCyte is offering an exclusive offer to G-Rex grant recipients. Use MaxCyte’s proven platform and extensive expertise to minimize risks in your cell therapy programs.
About MaxCyte, Inc.
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world’s most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as four commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady’s expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex Grant Program, please contact [email protected].
About Wilson Wolf Manufacturing
Wilson Wolf is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf’s mission is to create hope for cancer patients, one G-Rex device at a time.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 6, 2024. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.supremeclients.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
